Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
25 janv. 2023 08h00 HE
|
Denali Therapeutics Inc.
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to receive a milestone payment of $25 million from Sanofi for Phase 2...
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
09 janv. 2023 08h00 HE
|
Denali Therapeutics Inc.
Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’s diseaseFurther validation and expansion of Transport Vehicle (TV) technology,...
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
05 déc. 2022 07h00 HE
|
Denali Therapeutics Inc.
DNL343 demonstrated extensive blood-brain barrier penetration and robustly inhibited the integrated stress response pathway implicated in ALSOnce-daily oral dosing with DNL343 for 28 days was...
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
03 nov. 2022 16h01 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
01 nov. 2022 08h00 HE
|
Denali Therapeutics Inc.
Interim results from Part A in healthy volunteers demonstrated dose-dependent increases in CSF progranulin levels, consistent with robust brain delivery of DNL593Single doses of DNL593 were generally...
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
24 oct. 2022 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 11,933,962 shares of...
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
19 oct. 2022 21h19 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its...
Denali Therapeutics Announces Proposed Offering of Common Stock
18 oct. 2022 16h40 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in...
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
03 oct. 2022 08h00 HE
|
Denali Therapeutics Inc.
Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2LRRK2 mutations are one of the most common genetic drivers of Parkinson’s diseaseTargeting LRRK2 has...
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
31 août 2022 08h00 HE
|
Denali Therapeutics Inc.
Additional one-year data continue to show rapid and sustained normalization to healthy levels of CSF heparan sulfate and improvements in biomarkers of lysosomal function consistent with durable...